Table 3. Subgroup analysis according to the definitions for PGD.
| No.of studies | Test for association | Test for subgroup difference | |||
| OR (95% CI) | P | I2 | P | ||
| Age | 0% | 0.72 | |||
| ISHLT | 5 | −1.33 (−5.09 to 2.43) | 0.49 | ||
| Othe definitions | 5 | −0.58 (−2.17 to 1.10) | 0.48 | ||
| Female | 0% | 0.33 | |||
| ISHLT | 8 | 1.21 (0.82 to 1.77) | 0.33 | ||
| Othe definitions | 4 | 1.50 (1.23 to 1.83) | <0.001 | ||
| Race | |||||
| African-American | 36% | 0.21 | |||
| ISPGS | 3 | 2.28 (1.55 to 3.36) | <0.001 | ||
| Othe definitions | 3 | 1.37 (0.68 to 2.74) | 0.38 | ||
| Diagnosis | |||||
| IPF | 0% | 0.58 | |||
| ISHLT | 5 | 1.88 (1.40 to 2.54) | <0.001 | ||
| Othe definitions | 5 | 1.65 (1.14 to 2.38) | 0.0009 | ||
| Cystic fibrosis | 0% | 0.71 | |||
| ISHLT | 5 | 1.41 (0.63 to 3.18) | 0.41 | ||
| Othe definitions | 3 | 1.20 (0.93 to 1.55) | 0.16 | ||
| PPH | 0% | 0.61 | |||
| ISHLT | 5 | 6.58 (1.04 to 41.59) | <0.001 | ||
| Othe definitions | 3 | 4.04 (3.12 to 5.24) | 0.05 | ||
| Mean PAP | 0% | 0.61 | |||
| ISHLT | 4 | 5.80 (1.65 to 9.94) | 0.006 | ||
| Othe definitions | 3 | 6.93 (5.69 to 8.17) | <0.001 | ||
| BLT vs SLT | 0% | 0.73 | |||
| ISHLT | 6 | 1.06 (0.84 to 1.33) | 0.63 | ||
| Othe definitions | 5 | 1.11 (0.96 to 1.28) | 0.15 | ||
| CPB | 0% | 0.77 | |||
| ISHLT | 7 | 2.31 (1.23 to 4.33) | 0.009 | ||
| Othe definitions | 4 | 2.62 (1.47 to 4.66) | 0.001 | ||
| Use of inhaled NO | 0% | 0.69 | |||
| ISHLT | 2 | 1.22 (0.59 to 2.51) | 0.60 | ||
| Othe definitions | 2 | 1.00 (0.54 to 1.85) | 0.99 | ||
PGD, primary graft dysfunction; ISHLT, International Society for Heart and Lung Transplantation; IPF, idiopathic pulmonary fibrosis; PPH, primary pulmonary hypertension; PAP, pulmonary artery pressure; BLT, bilateral lung transplant; SLT, single lung transplant; CPB, cardiopulmonary bypass; NO, nitric oxide.